http://www.streetinsider.com Latest StreetInsider.com News Articles en-us Copyright 2026, StreetInsider.com rss@streetinsider.com (SI RSS) rss@streetinsider.com (SI RSS) Thu, 23 Jul 2026 07:30:00 -0400 http://blogs.law.harvard.edu/tech/rss http://www.streetinsider.com/images/rss_logo.gif http://www.streetinsider.com 143 28 0 1 2 3 21 22 23 Saturday Sunday http://www.streetinsider.com/Press+Releases/Xeris+Biopharma+to+Report+Second+Quarter+2026+Financial+Results+on+August+6%2C+2026/26804587.html <p class="bwalignc"> <b>Conference Call to be Held at 8:30 a.m. ET</b> </p> <p> CHICAGO--(BUSINESS WIRE)--</p> <p class="bwalignl"> Xeris Biopharma Holdings, Inc. (Nasdaq: XERS), a fast-growing biopharmaceutical company committed to improving patient lives by developing and commercializing innovative products across a range of therapies, today announced that the Company will release its second quarter 2026 financial results before the open of the U.S. financial markets on Thursday, August 6, 2026. Management will host a conference call and webcast at 8:30 a.m. Eastern Time that day to discuss the Company’s financial and operational results. </p><p> Interested parties may pre-register for the call <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fevents.q4inc.com%2Fattendee%2F250146676&amp;esheet=54575074&amp;newsitemid=20260723610212&amp;lan=en-US&amp;anchor=here&amp;index=1&amp;md5=aeb3386cb499234b01e7f8e4ab4d4614" http://www.streetinsider.com/Press+Releases/Xeris+Biopharma+to+Report+Second+Quarter+2026+Financial+Results+on+August+6%2C+2026/26804587.html Thu, 23 Jul 2026 07:30:00 -0400 O.25198597 XERS http://www.streetinsider.com/Press+Releases/Xeris+Biopharma+to+Report+Second+Quarter+2026+Financial+Results+on+August+6%2C+2026/26804587.html <p class="bwalignc"> <b>Conference Call to be Held at 8:30 a.m. ET</b> </p> <p> CHICAGO--(BUSINESS WIRE)--</p> <p class="bwalignl"> Xeris Biopharma Holdings, Inc. (Nasdaq: XERS), a fast-growing biopharmaceutical company committed to improving patient lives by developing and commercializing innovative products across a range of therapies, today announced that the Company will release its second quarter 2026 financial results before the open of the U.S. financial markets on Thursday, August 6, 2026. Management will host a conference call and webcast at 8:30 a.m. Eastern Time that day to discuss the Company’s financial and operational results. </p><p> Interested parties may pre-register for the call <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fevents.q4inc.com%2Fattendee%2F250146676&amp;esheet=54575074&amp;newsitemid=20260723610212&amp;lan=en-US&amp;anchor=here&amp;index=1&amp;md5=aeb3386cb499234b01e7f8e4ab4d4614" http://www.streetinsider.com/Press+Releases/Xeris+Biopharma+to+Report+Second+Quarter+2026+Financial+Results+on+August+6%2C+2026/26804587.html Thu, 23 Jul 2026 07:30:00 -0400 O.25198597 XERS http://www.streetinsider.com/Business+Wire/Xeris+Biopharma+to+Report+Second+Quarter+2026+Financial+Results+on+August+6%2C+2026/26804587.html <p class="bwalignc"> <b>Conference Call to be Held at 8:30 a.m. ET</b> </p> <p> CHICAGO--(BUSINESS WIRE)--</p> <p class="bwalignl"> Xeris Biopharma Holdings, Inc. (Nasdaq: XERS), a fast-growing biopharmaceutical company committed to improving patient lives by developing and commercializing innovative products across a range of therapies, today announced that the Company will release its second quarter 2026 financial results before the open of the U.S. financial markets on Thursday, August 6, 2026. Management will host a conference call and webcast at 8:30 a.m. Eastern Time that day to discuss the Company’s financial and operational results. </p><p> Interested parties may pre-register for the call <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fevents.q4inc.com%2Fattendee%2F250146676&amp;esheet=54575074&amp;newsitemid=20260723610212&amp;lan=en-US&amp;anchor=here&amp;index=1&amp;md5=aeb3386cb499234b01e7f8e4ab4d4614" http://www.streetinsider.com/Business+Wire/Xeris+Biopharma+to+Report+Second+Quarter+2026+Financial+Results+on+August+6%2C+2026/26804587.html Thu, 23 Jul 2026 07:30:00 -0400 O.25198597 XERS http://www.streetinsider.com/Business+Wire/Xeris+Biopharma+to+Report+Second+Quarter+2026+Financial+Results+on+August+6%2C+2026/26804587.html <p class="bwalignc"> <b>Conference Call to be Held at 8:30 a.m. ET</b> </p> <p> CHICAGO--(BUSINESS WIRE)--</p> <p class="bwalignl"> Xeris Biopharma Holdings, Inc. (Nasdaq: XERS), a fast-growing biopharmaceutical company committed to improving patient lives by developing and commercializing innovative products across a range of therapies, today announced that the Company will release its second quarter 2026 financial results before the open of the U.S. financial markets on Thursday, August 6, 2026. Management will host a conference call and webcast at 8:30 a.m. Eastern Time that day to discuss the Company’s financial and operational results. </p><p> Interested parties may pre-register for the call <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fevents.q4inc.com%2Fattendee%2F250146676&amp;esheet=54575074&amp;newsitemid=20260723610212&amp;lan=en-US&amp;anchor=here&amp;index=1&amp;md5=aeb3386cb499234b01e7f8e4ab4d4614" http://www.streetinsider.com/Business+Wire/Xeris+Biopharma+to+Report+Second+Quarter+2026+Financial+Results+on+August+6%2C+2026/26804587.html Thu, 23 Jul 2026 07:30:00 -0400 O.25198597 XERS http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Xeris+Biopharma+Holdings++For%3A+Jul+15/26784602.html si-local-file:///var/storage/secattach/20260717/26784602.html http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Xeris+Biopharma+Holdings++For%3A+Jul+15/26784602.html Fri, 17 Jul 2026 16:21:00 -0400 O.25198597 XERS http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Xeris+Biopharma+Holdings++For%3A+Jul+15/26784602.html si-local-file:///var/storage/secattach/20260717/26784602.html http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Xeris+Biopharma+Holdings++For%3A+Jul+15/26784602.html Fri, 17 Jul 2026 16:21:00 -0400 O.25198597 XERS http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Xeris+Biopharma+Holdings++For%3A+Jul+06++Filed+by%3A+Pieper+Steven/26742655.html si-local-file:///var/storage/secattach/20260707/26742655.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Xeris+Biopharma+Holdings++For%3A+Jul+06++Filed+by%3A+Pieper+Steven/26742655.html Tue, 07 Jul 2026 17:11:00 -0400 O.25198597 XERS http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Xeris+Biopharma+Holdings++For%3A+Jul+06++Filed+by%3A+Pieper+Steven/26742655.html si-local-file:///var/storage/secattach/20260707/26742655.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Xeris+Biopharma+Holdings++For%3A+Jul+06++Filed+by%3A+Pieper+Steven/26742655.html Tue, 07 Jul 2026 17:11:00 -0400 O.25198597 XERS http://www.streetinsider.com/SEC+Filings/Form++144++++++++Xeris+Biopharma+Holdings+++++++++++++++Filed+by%3A+Pieper+Steven/26742280.html si-local-file:///var/storage/secattach/20260707/26742280.html http://www.streetinsider.com/SEC+Filings/Form++144++++++++Xeris+Biopharma+Holdings+++++++++++++++Filed+by%3A+Pieper+Steven/26742280.html Tue, 07 Jul 2026 16:38:00 -0400 O.25198597 XERS http://www.streetinsider.com/SEC+Filings/Form++144++++++++Xeris+Biopharma+Holdings+++++++++++++++Filed+by%3A+Pieper+Steven/26742280.html si-local-file:///var/storage/secattach/20260707/26742280.html http://www.streetinsider.com/SEC+Filings/Form++144++++++++Xeris+Biopharma+Holdings+++++++++++++++Filed+by%3A+Pieper+Steven/26742280.html Tue, 07 Jul 2026 16:38:00 -0400 O.25198597 XERS http://www.streetinsider.com/SEC+Filings/Form++144++++++++Xeris+Biopharma+Holdings+++++++++++++++Filed+by%3A+Pieper+Steven/26736142.html si-local-file:///var/storage/secattach/20260706/26736142.html http://www.streetinsider.com/SEC+Filings/Form++144++++++++Xeris+Biopharma+Holdings+++++++++++++++Filed+by%3A+Pieper+Steven/26736142.html Mon, 06 Jul 2026 16:39:00 -0400 O.25198597 XERS http://www.streetinsider.com/SEC+Filings/Form++144++++++++Xeris+Biopharma+Holdings+++++++++++++++Filed+by%3A+Pieper+Steven/26736142.html si-local-file:///var/storage/secattach/20260706/26736142.html http://www.streetinsider.com/SEC+Filings/Form++144++++++++Xeris+Biopharma+Holdings+++++++++++++++Filed+by%3A+Pieper+Steven/26736142.html Mon, 06 Jul 2026 16:39:00 -0400 O.25198597 XERS http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Xeris+Biopharma+Holdings++For%3A+Jul+01++Filed+by%3A+KREHER+NERISSA/26729844.html si-local-file:///var/storage/secattach/20260702/26729844.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Xeris+Biopharma+Holdings++For%3A+Jul+01++Filed+by%3A+KREHER+NERISSA/26729844.html Thu, 02 Jul 2026 18:02:00 -0400 O.25198597 XERS http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Xeris+Biopharma+Holdings++For%3A+Jul+01++Filed+by%3A+KREHER+NERISSA/26729844.html si-local-file:///var/storage/secattach/20260702/26729844.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Xeris+Biopharma+Holdings++For%3A+Jul+01++Filed+by%3A+KREHER+NERISSA/26729844.html Thu, 02 Jul 2026 18:02:00 -0400 O.25198597 XERS http://www.streetinsider.com/SEC+Filings/Form++3++++++++++Xeris+Biopharma+Holdings++For%3A+Jul+01++Filed+by%3A+KREHER+NERISSA/26729824.html si-local-file:///var/storage/secattach/20260702/26729824.html http://www.streetinsider.com/SEC+Filings/Form++3++++++++++Xeris+Biopharma+Holdings++For%3A+Jul+01++Filed+by%3A+KREHER+NERISSA/26729824.html Thu, 02 Jul 2026 18:00:00 -0400 O.25198597 XERS http://www.streetinsider.com/SEC+Filings/Form++3++++++++++Xeris+Biopharma+Holdings++For%3A+Jul+01++Filed+by%3A+KREHER+NERISSA/26729824.html si-local-file:///var/storage/secattach/20260702/26729824.html http://www.streetinsider.com/SEC+Filings/Form++3++++++++++Xeris+Biopharma+Holdings++For%3A+Jul+01++Filed+by%3A+KREHER+NERISSA/26729824.html Thu, 02 Jul 2026 18:00:00 -0400 O.25198597 XERS http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Xeris+Biopharma+Holdings++For%3A+Jul+01++Filed+by%3A+McCulloch+Kevin/26728790.html si-local-file:///var/storage/secattach/20260702/26728790.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Xeris+Biopharma+Holdings++For%3A+Jul+01++Filed+by%3A+McCulloch+Kevin/26728790.html Thu, 02 Jul 2026 16:41:00 -0400 O.25198597 XERS http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Xeris+Biopharma+Holdings++For%3A+Jul+01++Filed+by%3A+McCulloch+Kevin/26728790.html si-local-file:///var/storage/secattach/20260702/26728790.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Xeris+Biopharma+Holdings++For%3A+Jul+01++Filed+by%3A+McCulloch+Kevin/26728790.html Thu, 02 Jul 2026 16:41:00 -0400 O.25198597 XERS http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Xeris+Biopharma+Holdings++For%3A+Jul+01++Filed+by%3A+Hecht+Beth/26728728.html si-local-file:///var/storage/secattach/20260702/26728728.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Xeris+Biopharma+Holdings++For%3A+Jul+01++Filed+by%3A+Hecht+Beth/26728728.html Thu, 02 Jul 2026 16:39:00 -0400 O.25198597 XERS http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Xeris+Biopharma+Holdings++For%3A+Jul+01++Filed+by%3A+Hecht+Beth/26728728.html si-local-file:///var/storage/secattach/20260702/26728728.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Xeris+Biopharma+Holdings++For%3A+Jul+01++Filed+by%3A+Hecht+Beth/26728728.html Thu, 02 Jul 2026 16:39:00 -0400 O.25198597 XERS http://www.streetinsider.com/Press+Releases/Xeris+Announces+Inducement+Grants+Under+Nasdaq+Listing+Rule+5635%28C%29%284%29/26727498.html <p> CHICAGO--(BUSINESS WIRE)-- Xeris Biopharma Holdings, Inc. (Nasdaq: XERS), a fast-growing biopharmaceutical company committed to improving patient lives by developing and commercializing innovative products across a range of therapies, today announced that on July 1, 2026, the Compensation Committee of Xeris’ Board of Directors granted restricted stock units for an aggregate of 221,323 shares of its common stock to 47 new employees under Xeris’ Inducement Equity Plan. </p><p> Xeris’ Inducement Equity Plan is used exclusively for the grant of equity awards to individuals who were not previously employed by Xeris or one of its subsidiaries as an inducement material to http://www.streetinsider.com/Press+Releases/Xeris+Announces+Inducement+Grants+Under+Nasdaq+Listing+Rule+5635%28C%29%284%29/26727498.html Thu, 02 Jul 2026 16:05:00 -0400 O.25198597 XERS http://www.streetinsider.com/Press+Releases/Xeris+Announces+Inducement+Grants+Under+Nasdaq+Listing+Rule+5635%28C%29%284%29/26727498.html <p> CHICAGO--(BUSINESS WIRE)-- Xeris Biopharma Holdings, Inc. (Nasdaq: XERS), a fast-growing biopharmaceutical company committed to improving patient lives by developing and commercializing innovative products across a range of therapies, today announced that on July 1, 2026, the Compensation Committee of Xeris’ Board of Directors granted restricted stock units for an aggregate of 221,323 shares of its common stock to 47 new employees under Xeris’ Inducement Equity Plan. </p><p> Xeris’ Inducement Equity Plan is used exclusively for the grant of equity awards to individuals who were not previously employed by Xeris or one of its subsidiaries as an inducement material to http://www.streetinsider.com/Press+Releases/Xeris+Announces+Inducement+Grants+Under+Nasdaq+Listing+Rule+5635%28C%29%284%29/26727498.html Thu, 02 Jul 2026 16:05:00 -0400 O.25198597 XERS http://www.streetinsider.com/Business+Wire/Xeris+Announces+Inducement+Grants+Under+Nasdaq+Listing+Rule+5635%28C%29%284%29/26727498.html <p> CHICAGO--(BUSINESS WIRE)-- Xeris Biopharma Holdings, Inc. (Nasdaq: XERS), a fast-growing biopharmaceutical company committed to improving patient lives by developing and commercializing innovative products across a range of therapies, today announced that on July 1, 2026, the Compensation Committee of Xeris’ Board of Directors granted restricted stock units for an aggregate of 221,323 shares of its common stock to 47 new employees under Xeris’ Inducement Equity Plan. </p><p> Xeris’ Inducement Equity Plan is used exclusively for the grant of equity awards to individuals who were not previously employed by Xeris or one of its subsidiaries as an inducement material to http://www.streetinsider.com/Business+Wire/Xeris+Announces+Inducement+Grants+Under+Nasdaq+Listing+Rule+5635%28C%29%284%29/26727498.html Thu, 02 Jul 2026 16:05:00 -0400 O.25198597 XERS http://www.streetinsider.com/Business+Wire/Xeris+Announces+Inducement+Grants+Under+Nasdaq+Listing+Rule+5635%28C%29%284%29/26727498.html <p> CHICAGO--(BUSINESS WIRE)-- Xeris Biopharma Holdings, Inc. (Nasdaq: XERS), a fast-growing biopharmaceutical company committed to improving patient lives by developing and commercializing innovative products across a range of therapies, today announced that on July 1, 2026, the Compensation Committee of Xeris’ Board of Directors granted restricted stock units for an aggregate of 221,323 shares of its common stock to 47 new employees under Xeris’ Inducement Equity Plan. </p><p> Xeris’ Inducement Equity Plan is used exclusively for the grant of equity awards to individuals who were not previously employed by Xeris or one of its subsidiaries as an inducement material to http://www.streetinsider.com/Business+Wire/Xeris+Announces+Inducement+Grants+Under+Nasdaq+Listing+Rule+5635%28C%29%284%29/26727498.html Thu, 02 Jul 2026 16:05:00 -0400 O.25198597 XERS http://www.streetinsider.com/Press+Releases/CORRECTING+and+REPLACING+Xeris+Announces+Inducement+Grants+Under+Nasdaq+Listing+Rule+5635%28C%29%284%29/26730336.html <p> CHICAGO--(BUSINESS WIRE)-- Please replace the release issued earlier today with the following corrected version that provides additional information regarding the inducement grants. </p><p> The corrected release reads: </p><p class="bwalignc"> <b>XERIS ANNOUNCES INDUCEMENT GRANTS UNDER NASDAQ LISTING RULE 5635(C)(4)</b> </p><p> Xeris Biopharma Holdings, Inc. (Nasdaq: XERS), a fast-growing biopharmaceutical company committed to improving patient lives by developing and commercializing innovative products across a range of therapies, today announced that on July 1, 2026, the Compensation Committee of Xeris’ Board of Directors granted a non-qualified stock option and restricted stock units for an aggregate of 221,323 shares of its common stock to 47 new employees http://www.streetinsider.com/Press+Releases/CORRECTING+and+REPLACING+Xeris+Announces+Inducement+Grants+Under+Nasdaq+Listing+Rule+5635%28C%29%284%29/26730336.html Thu, 02 Jul 2026 16:05:00 -0400 O.25198597 XERS